4//SEC Filing
Horizon Pharma plc 4
Accession 0001209191-14-069268
CIK 0001492426operating
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 5:18 PM ET
Size
6.6 KB
Accession
0001209191-14-069268
Insider Transaction Report
Form 4
Nohria Virinder
Director
Transactions
- Sale
Ordinary shares, nominal value $0.0001 per share
2014-11-13$11.54/sh−1,739,130$20,069,560→ 475,706 total
Footnotes (2)
- [F1]On November 13, 2014, Dr. Nohria agreed to sell 1,739,130 ordinary shares pursuant to that certain Underwriting Agreement, dated as of November 13, 2014 (the "Underwriting Agreement"), among the Issuer, the several selling shareholders (the "Selling Shareholders") named in Schedule I to the Underwriting Agreement and Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Cowen and Company, LLC and Jefferies LLC, as representatives of the several underwriters (the "Underwriters") named in Schedule II to the Underwriting Agreement. Dr. Nohria also granted the Underwriters the option to purchase an additional 260,870 ordinary shares. The number in the table above assumes no exercise by the Underwriters of their option to purchase additional shares. The price to the public was $12.05 per ordinary share and the proceeds to Dr. Nohria was $11.537875 per ordinary share.
- [F2](continued from footnote 1) In addition, in connection with the sale of ordinary shares, the Issuer also agreed to pay an aggregate of $2,230,231 to Altiva Capital, LLC, Dr. Nohria and Mohun Patrick Nohria 2013 Gift Trust (the "Reimbursed Shareholders") in connection with the sale of the ordinary shares by such Reimbursed Shareholders pursuant to the Underwriting Agreement, provided, that if the several Underwriters exercise their right to purchase the additional shares pursuant to the Underwriting Agreement in full or in part, the Issuer shall pay the Reimbursed Shareholders an additional $334,535 which shall be reduced pro rata in the event of that all additional shares are not purchased, in each case, each Reimbursed Shareholder to receive its pro rata amount based on the number of shares to be sold by such Reimbursed Shareholder (or $0.262125 per share).
Documents
Issuer
Horizon Pharma plc
CIK 0001492426
Entity typeoperating
IncorporatedIreland
Related Parties
1- filerCIK 0001492426
Filing Metadata
- Form type
- 4
- Filed
- Nov 16, 7:00 PM ET
- Accepted
- Nov 17, 5:18 PM ET
- Size
- 6.6 KB